BioSpace News Archive

Policy

AstraZeneca to Pay Pfizer $107.5M in Damages in Tagrisso Patent Tussle

Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.

May 20, 2024
·
2 min read
·
Tristan Manalac
Drug Delivery

AstraZeneca to Build $1.5B ADC Manufacturing Plant in Singapore

To support its growing antibody-drug conjugate portfolio, AstraZeneca on Monday said it is investing $1.5 billion in a Singapore production site that will include all steps of the ADC manufacturing process.

May 20, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.

May 20, 2024
·
5 min read
·
Mollie Barnes
Can AI Help Biopharma Companies Go Green?

The insights AI affords can potentially boost sustainability, but it’s unclear whether these gains outweigh the technology’s environmental cost.

May 20, 2024
·
6 min read
·
Sanjukta Mondal
Drug Development

30 Years After Genetic Discovery, Huntington’s Patients Still Waiting

Following a series of clinical failures, optimism builds for the first disease-modifying treatment.

May 20, 2024
·
6 min read
·
Heather McKenzie
Drug Development

GLP-1 Receptor Agonist Market to Reach $125B by 2033: GlobalData

While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in clinical development for obesity and type 2 diabetes, according to analytics firm GlobalData.

May 20, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Moderna Gets Win in COVID-19 Patent Dispute with Pfizer, BioNTech

The European Patent Office last week upheld one of Moderna’s key patents, handing the biotech an important victory in its protracted COVID-19 vaccine battle with Pfizer and BioNTech.

May 20, 2024
·
2 min read
·
Tristan Manalac
Deals

Rapport Therapeutics and Telix Pharma File IPOs as Number of Biotechs Going Public Slows

Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.

May 20, 2024
·
2 min read
·
Kate Goodwin
Drug Development

Gilead Touts Phase III Results for Liver Disease Drug Ahead of PDUFA Date

Seladelpar, which Gilead acquired when it bought CymaBay in February for $4.3 billion, showed positive results for reducing pruritus in primary biliary cholangitis patients and reducing inflammation.

May 20, 2024
·
2 min read
·
Tyler Patchen
Pharming Group to participate in May 2024 investor conference

Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of May.

May 20, 2024
·
1 min read